Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Dementia Risk in Type 2 Diabetes: A Comprehensive Bayesian Network Meta-Analysis

Related

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• GLP-1 agonists linked to lower dementia risk after COVID-19

  Drug Design, Development and Therapy · 5 Oct 2026

  

• COVID-19 tied to higher dementia risk in older adults with diabetes

  Frontiers in Aging Neuroscience · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026